Fluoxetine, best known by the brand name Prozac, works by blocking the serotonin transporter in the brain, but its journey through the body is what shapes everything from how quickly it kicks in to why missing a dose rarely triggers withdrawal. The drug is absorbed well from the gut, heavily bound to proteins in the blood, and broken down in the liver into an active metabolite called norfluoxetine that sticks around even longer than the parent drug. That unusually long residence time sets fluoxetine apart from nearly every other antidepressant on the market and has real consequences for the people who take it.
What Fluoxetine Does Once It Reaches the Brain
Fluoxetine’s primary job is to block the serotonin transporter, a protein on the surface of nerve cells that normally vacuums serotonin out of the gap between neurons after it has delivered its signal. By sitting in the transporter and preventing reuptake, fluoxetine keeps serotonin available in the synapse longer. The transporter binds fluoxetine more tightly when chloride ions are present, which is relevant because chloride concentrations vary across different brain regions and may partly explain why the drug’s effects are not uniform throughout the brain.1PubMed Central. Fluoxetine (Prozac) binding to serotonin transporter is modulated by chloride and conformational changes
That is the textbook explanation, but it is not the whole story. Fluoxetine also blocks certain serotonin receptors (specifically the 5-HT2C subtype), acting as an antagonist rather than simply boosting serotonin levels. Researchers have demonstrated that fluoxetine competitively and reversibly blocks 5-HT2C receptors, and this action may contribute to some of its therapeutic effects and its appetite-suppressing side effects.2PubMed Central. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac)
A more recent discovery adds another layer. A 2021 study published in Cell found that fluoxetine and other antidepressants directly bind to TRKB, a receptor for the brain growth factor BDNF. By latching onto the transmembrane portion of TRKB, fluoxetine promotes synaptic plasticity, which is the brain’s ability to rewire connections. The researchers proposed that this TRKB-mediated effect may be the common mechanism behind why antidepressants eventually improve mood, and it could explain the weeks-long delay between starting the drug and feeling better: the brain needs time to physically reorganize.3PubMed Central. Antidepressant drugs act by directly binding to TRKB neurotrophin receptors Fluoxetine’s affinity for the serotonin transporter is much higher than its affinity for TRKB, but the concentrations that build up in the brain during chronic treatment are high enough to engage both targets.4Cell. Antidepressants act by directly binding to TRKB neurotrophin receptors
Absorption and Distribution
Fluoxetine is well absorbed after you swallow it, whether as a capsule, tablet, or liquid. Food can slow absorption slightly but does not meaningfully change how much of the drug ends up in your bloodstream, so it can be taken with or without meals.5PubMed. Clinical pharmacokinetics of fluoxetine
Once in the blood, about 94% of fluoxetine latches onto plasma proteins, primarily albumin. Only the remaining 6% floats free, and that unbound fraction is the portion available to cross into tissues and act on the brain.6PubMed Central. Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day This heavy protein binding matters clinically. If another highly protein-bound drug is added, the two can compete for binding sites, briefly increasing the free concentration of one or both. In practice, this is rarely a major issue with fluoxetine, but it is one of several reasons prescribers track a patient’s full medication list.
Fluoxetine also has a large volume of distribution, meaning it spreads widely into tissues rather than staying concentrated in the blood. It accumulates in the brain, lungs, liver, and other organs. This extensive tissue distribution is part of why the drug takes a long time to wash out of the body completely after you stop taking it.
How the Liver Breaks It Down
The liver handles the heavy lifting of fluoxetine metabolism, and the process produces something unusual: an active metabolite that is pharmacologically potent in its own right. The main metabolic step is called N-demethylation, which strips off a methyl group and converts fluoxetine into norfluoxetine. Norfluoxetine also blocks serotonin reuptake, so both the parent drug and its breakdown product contribute to the antidepressant effect.7PubMed Central. Factors associated with fluoxetine and norfluoxetine plasma concentrations and clinical response in Mexican patients with mental disorders
Several liver enzymes carry out this conversion. The main one is CYP2D6, but CYP2C9 and CYP3A4 also contribute meaningfully. Scaled estimates from human liver tissue suggest that these three enzymes together account for the bulk of fluoxetine’s breakdown.8PubMed. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes The involvement of multiple enzymes gives the body some redundancy: if one pathway is sluggish (because of genetics, other medications, or liver damage), the others can partially compensate.
There is a twist, though. Fluoxetine is not just broken down by CYP2D6; it also inhibits CYP2D6. The same enzyme responsible for metabolizing the drug gets progressively blocked by it. Research describes fluoxetine as a mechanism-based inhibitor of CYP2C19 as well.9PubMed Central. Assessing the Mechanism of Fluoxetine-Mediated CYP2D6 Inhibition This enzyme inhibition is the root of many of fluoxetine’s drug interactions.
The Unusually Long Half-Life
If you have heard one pharmacokinetic fact about fluoxetine, it is probably that the drug lingers. The elimination half-life of fluoxetine itself is roughly two to three days after a single dose. Norfluoxetine’s half-life is even longer, stretching to roughly four to sixteen days depending on the individual. Most other selective serotonin reuptake inhibitors have half-lives measured in hours, around one day at most.10PubMed. Pharmacokinetics of the selective serotonin reuptake inhibitors
Because of these long half-lives, steady-state blood levels are not reached for weeks after starting or changing a dose. With drugs like paroxetine or fluvoxamine, steady state arrives in about one to two weeks. With fluoxetine and especially norfluoxetine, it takes considerably longer. This is part of why a prescriber will usually wait several weeks before deciding whether a dose adjustment is needed.
The slow washout also means that after you stop taking fluoxetine, active drug and metabolite continue circulating for weeks. A randomized, placebo-controlled study found that abruptly stopping fluoxetine was well tolerated, with no cluster of symptoms resembling the discontinuation syndrome commonly seen with shorter-acting antidepressants.11Journal of Clinical Psychopharmacology. Safety of Abrupt Discontinuation of Fluoxetine: A Randomized, Placebo-Controlled Study This has led some clinicians to use fluoxetine as a bridge drug when tapering patients off other antidepressants. A recent proposal outlines a standardized fluoxetine substitution protocol designed to help patients discontinue other serotonin reuptake inhibitors while keeping withdrawal symptoms at bay.12PubMed Central. Fluoxetine substitution for deprescribing antidepressants: a technical approach
Why Genetics Change the Picture
Because CYP2D6 plays a central role in converting fluoxetine to norfluoxetine, genetic variation in the CYP2D6 gene has measurable effects on how the drug behaves. People are categorized into metabolizer phenotypes based on how many functional copies of the gene they carry. Poor metabolizers have little or no CYP2D6 activity, intermediate metabolizers have reduced activity, normal metabolizers have typical activity, and ultrarapid metabolizers have extra.
A study in adults found that poor metabolizers had fluoxetine concentrations about 70% higher, and norfluoxetine concentrations about 51% lower, than normal metabolizers given the same dose. Intermediate metabolizers showed the same pattern but less dramatically. Ultrarapid metabolizers, on the other hand, had higher metabolic ratios of norfluoxetine to fluoxetine, meaning they convert the parent drug faster.13PubMed Central. Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children/adolescents
Here is the nuance, though: when researchers look at the “active moiety,” meaning the combined concentration of fluoxetine plus norfluoxetine (both of which block serotonin reuptake), the differences between metabolizer groups largely wash out. The same study found no significant association between CYP2D6 phenotype and the active moiety’s concentration. An earlier study reached a similar conclusion, finding no statistically significant relationship between genotype and the combined active compound levels at steady state.14PubMed. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine In other words, a slow metabolizer ends up with more fluoxetine and less norfluoxetine, while a fast metabolizer gets the opposite mix, but the total active drug stays roughly similar. This is one reason fluoxetine tends to be more forgiving across different genetic backgrounds than some other antidepressants. That said, the ratio still matters for side-effect profiles and drug interactions, since fluoxetine and norfluoxetine are not identical in their receptor activities.
The Mirror-Image Molecule Problem
Fluoxetine is sold as a racemic mixture, meaning each pill contains equal amounts of two mirror-image forms: R-fluoxetine and S-fluoxetine. These two forms are not handled identically by the body. The metabolism is enantioselective, meaning the liver enzymes prefer one form over the other to different degrees depending on which enzyme is doing the work.15PubMed Central. Enantioselective analysis of fluoxetine in pharmaceutical formulations by capillary zone electrophoresis CYP2C9, for example, shows a preference for R-fluoxetine over S-fluoxetine.8PubMed. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes
Protein binding also differs between the two forms. Animal studies show that R-fluoxetine has a higher clearance and volume of distribution than S-fluoxetine, largely because the S form is more tightly bound to plasma proteins.16Drug Metabolism and Disposition. Stereoselective Pharmacokinetics of Fluoxetine and Norfluoxetine Enantiomers in Pregnant Sheep The practical upshot for patients is that S-fluoxetine, which is the more pharmacologically active enantiomer for serotonin reuptake inhibition, tends to accumulate to higher levels relative to R-fluoxetine. This stereoselective behavior becomes especially relevant during pregnancy, as discussed below.
Liver Disease, Kidney Disease, and Pediatric Patients
Since the liver is fluoxetine’s main processing plant, liver disease has a dramatic effect. In patients with stable alcoholic cirrhosis, the elimination half-life of fluoxetine roughly tripled compared to healthy volunteers, going from about 2.2 days to 6.6 days. Plasma clearance dropped by more than half. Formation and clearance of norfluoxetine were both reduced as well, which means both compounds accumulate at higher levels unless the dose is lowered.17PubMed. Fluoxetine disposition and elimination in cirrhosis
Kidney disease, by contrast, is largely a non-issue. Studies have found that mild, moderate, or even severe renal dysfunction does not significantly alter fluoxetine or norfluoxetine levels.18PubMed. The effects of renal and hepatic disease on the pharmacokinetics, renal tolerance, and risk-benefit profile of fluoxetine No correlation between the degree of kidney impairment and elimination rate, distribution volume, or protein binding was found in an earlier study either.19PubMed. Fluoxetine kinetics and protein binding in normal and impaired renal function This makes sense because very little fluoxetine is excreted unchanged in urine; the liver does virtually all the heavy lifting, and the kidneys eliminate the downstream metabolites that have already been rendered inactive.
In children and adolescents, the accumulation profile and steady-state concentrations are similar to those seen in adults.20PubMed. Fluoxetine pharmacokinetics in pediatric patients When doses are adjusted for body weight, the differences between children and adults largely disappear.21PubMed. Fluoxetine pharmacogenetics in child and adult populations
Pregnancy and Breastfeeding
Fluoxetine crosses the placenta readily. At delivery, infant plasma concentrations of fluoxetine and norfluoxetine have been measured at roughly 65% and 72% of maternal concentrations, respectively.22PubMed. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation A separate study found even higher fetal-to-maternal ratios in cord blood, with norfluoxetine approaching a 1:1 ratio.23PubMed Central. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding
The stereochemistry adds a layer of concern. The S-to-R ratios in the fetus and newborn are significantly higher than in the mother, meaning the fetus is disproportionately exposed to the more pharmacologically active S-enantiomers of both fluoxetine and norfluoxetine.23PubMed Central. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding This does not automatically mean harm, but it does mean that simply looking at total drug concentrations underestimates the fetal exposure to the active forms.
Fluoxetine also passes into breast milk. One study estimated total infant exposure through breast milk at roughly 2% to 4% of the maternal weight-adjusted dose at two weeks and two months after delivery.22PubMed. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation Another study reported a higher estimate, with mean total infant exposure reaching about 7% of the maternal weight-adjusted dose, and individual infants ranging from about 2% to 12%.24PubMed Central. Distribution and excretion of fluoxetine and norfluoxetine in human milk Neonates who were exposed in utero tended to have higher concentrations at birth and appeared to be at greater risk of effects than those exposed only through breast milk after birth. These findings do not settle the question of whether fluoxetine is safe to use during pregnancy or breastfeeding, which depends on weighing the risks of untreated depression against the risks of fetal drug exposure, a decision best made with a prescriber who knows the patient’s full situation.
Drug Interactions Driven by Enzyme Inhibition
Fluoxetine’s inhibition of CYP2D6 means it can raise blood levels of any other drug that depends on CYP2D6 for clearance. The list is long and includes certain beta-blockers, antipsychotics, opioid pain medications, and other antidepressants. Because norfluoxetine also inhibits CYP2D6 and sticks around for weeks, these interactions persist long after fluoxetine itself is discontinued.
One of the most clinically significant interactions involves tamoxifen, a drug used in breast cancer treatment. Tamoxifen is a prodrug that must be converted by CYP2D6 into its active form, endoxifen, to work properly. When fluoxetine inhibits CYP2D6, endoxifen formation drops substantially, potentially undermining tamoxifen’s anticancer effect. Guidelines now recommend avoiding potent CYP2D6-inhibiting antidepressants like fluoxetine and paroxetine in patients taking tamoxifen.25PubMed. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen Antidepressants with weaker CYP2D6 inhibition, such as venlafaxine or citalopram, are generally considered safer alternatives in this context.
What Happens in Overdose
Fluoxetine has a wider safety margin in overdose than older antidepressants like tricyclics, but high doses are not harmless. At toxic concentrations, both fluoxetine and norfluoxetine can block hERG potassium channels in the heart through two distinct mechanisms: directly plugging the channel and disrupting the trafficking of channel proteins to the cell surface. The result can be a prolonged QT interval on an electrocardiogram, which in severe cases can trigger a dangerous heart rhythm called torsades de pointes.26PubMed Central. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine
The long half-life creates a particular risk in overdose situations: life-threatening complications can appear late. A case report documented a patient who developed torsades de pointes well into their hospital stay after a multi-drug overdose, with fluoxetine serum levels measured at 2700 micrograms per liter, far above the typical therapeutic range.27PubMed Central. Late presentation of Torsades de Pointes related to fluoxetine following a multiple drug overdose The implication is that patients who overdose on fluoxetine may need extended cardiac monitoring even if they look stable in the first hours, because the drug is still being absorbed from tissues and converted to an equally active metabolite during that time. Other overdose effects can include serotonin syndrome, seizures, and in rare cases, death, though fatalities from fluoxetine overdose alone remain uncommon compared to older antidepressant classes.
Why Brain Concentrations Are Not the Same as Blood Concentrations
One detail that trips people up is assuming that blood levels of fluoxetine directly predict what is happening in the brain. Because fluoxetine is highly lipophilic (fat-soluble) and accumulates preferentially in fatty tissue, brain concentrations can be many times higher than plasma concentrations. This extensive tissue penetration is part of why the drug works at relatively low blood levels and why tissue stores keep releasing the drug slowly even after blood levels start to fall. Modeling studies have confirmed that simulated concentration-time profiles in plasma match observed data well, but plasma is only one compartment in a multi-compartment system.6PubMed Central. Fluoxetine pharmacokinetics and tissue distribution quantitatively supports a therapeutic role in COVID-19 at a minimum dose of 20 mg per day The practical takeaway is that therapeutic drug monitoring via blood draws, while occasionally useful, does not capture the full picture of how much active drug is sitting in brain tissue at any given moment. This helps explain why two patients on the same dose can have very different clinical responses despite similar blood levels.